Clinical Trial ResultsPhase two study of VT1953 met primary and secondary endpoints in treating malignant fungating wounds, supporting plans to pursue a pivotal study and raising near-term clinical value visibility.
Financial StrengthLow cash burn, a clean balance sheet with no debt or warrants, available capital facilities and approximately seven million dollars in cash support operations into 2027 and provide flexibility to advance clinical programs.
Market OpportunityMalignant fungating wounds represent an addressable market exceeding one billion dollars with no FDA-approved therapies, positioning VT1953 for meaningful commercial upside if regulatory approval is achieved.